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ABSTRACT
The identification of pseudogenes is an integral and
significant part of the genome annotation because
of their abundance and their impact on the experi-
mental analysis of functional genes. Most of the
computational annotation systems are not optimi-
zed for systematic pseudogene recognition, often
annotating pseudogenes as functional genes, and
users then propagate these errors to subsequent
analyses and interpretations. In order to validate
gene annotations and to identify pseudogenes that
are potentially mis-annotated, we developed a novel
approach based on whole genome profiling of
existing transcript and protein sequences. This
method has two important features: (i) equally
detects both processed and non-processed pseu-
dogenes and (ii) can identify transcribed pseudo-
genes. Applying this method to the human Ensembl
gene predictions, we discovered that 2011 (9% of
total) Ensembl genes in the categories of known and
novel might be pseudogenes based on expression
evidence. Of these, 1200 genes are found to have no
existing evidence of transcription, and 811 genes
are found with transcription evidence but contain
significant translation disruption. Approximately
40% of the 2011 identified pseudogenes presented
a multi-exon structure, representing non-processed
pseudogenes. We have demonstrated the power of
whole genome profiling of expression sequences
to improve the accuracy of gene annotations.
INTRODUCTION
Pseudogenes are deﬁned as non-functional genomic
sequences derived from functional genes. The loss of function
is generally viewed as either a failure of transcription or
translation, or production of a defective protein (1,2). Most
pseudogenes are thought to be transcriptionally silent, but
transcribed pseudogenes have been experimentally identiﬁed
(3–10). Over the past several years, substantial efforts have
been devoted to genome-scale identiﬁcation and characteri-
zation of pseudogenes (11–15). However, none of these
methods is optimized for the detection of non-processed
pseudogenes that have retained the original exon/intron struc-
tures. Of these, the transcribed types have been known to be
especially problematic for gene annotation (16,17). Because
of the similarity to functional paralogs, pseudogenes are
often mis-incorporated into gene collections (18–21) intro-
ducing errors that propagate downstream to many subsequent
analyses. For example, a challenge of designing targeted
expression assays is to avoid cross-reacting paralogs, thus
by knowing which of the paralogs are reacting and non-
reacting pseudogenes, it will simplify the task of assay design
and result analysis.
Among the causes for mis-incorporation are (i) multiple
gene instantiations supported by one piece of evidence
aligned to multiple places on the genome and (ii) the use
of poor quality or fragmented evidence (22). Moreover,
most gene prediction algorithms were designed or trained
for detecting functional genes, but in practice, will make
pseudogenes into viable gene models by adjusting splicing
patterns (23). Accurate pseudogene annotation may ultima-
tely rely on manual curation, which is a labor-intensive and
time-consuming process.
Expression evidence, such as mRNA, expressed sequence
tags (ESTs) and protein sequences, could be potentially
mapped to many gene loci including its own locus, paralogs
and potential pseudogenes. In the process of gene annotation,
we have observed that these alignments usually have dif-
ferent degrees of match statistics, such as identity, coverage
and splicing status (see Figure 1), but the ‘best hit’ of any
given evidence is always associated with the originating
locus. This would then serve as conﬁrming evidence for
gene expression of that locus. In addition, we deﬁne a
pseudogene without conﬁrming transcriptional products as
non-transcribed pseudogene and one with transcriptional
products, but without translational products, as transcribed
pseudogene. We developed a novel bioinformatics method
*To whom correspondence should be addressed. Tel: +1 240 453 3154; Fax: +1 240 453 3587; Email: Peter.Li@appliedbiosystems.com
Present address:
Alison Yao, National Institute of Allergy and Infectious Diseases, NIH 6610 Rockledge Dr, Bethesda, MD 20892, USA
  2006 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Published online 31 August 2006 Nucleic Acids Research, 2006, Vol. 34, No. 16 4477–4485
doi:10.1093/nar/gkl591to systematically identify and validate pseudogenes by care-
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In this study, we applied the method on the Ensembl gene
annotation and the results are presented.
MATERIALS AND METHODS
Sequence data
We obtained the human genome assembly Build 35 from
NCBI (ftp://ftp.ncbi.nih.gov/genomes/H_sapiens/ARCHIVE/
BUILD.35.1/). The 25 assembled chromosome sequences
and 85 NT sequences were used as a reference genome.
The January 2005 release of the human mRNA and EST
sequences were extracted from the NCBI repositories: 22
887 sequences from a curated subset of the RefSeq experi-
mental mRNA database (24), 195073 sequences from Gen-
Bank mRNA database (25) and 6020341 sequences parsed
from the dbEST database (26). Human SWISS-PROT protein
sequences, a subset of protein sequences with high quality
annotation, were obtained from the SWISS-PROT database
in October 2004 (27) (http://www.ebi.ac.uk/swissprot/) and
11777 sequences were obtained.
Gene sets
The Ensembl gene (22) release 27.35a.1 was extracted from
Ensembl database (http://www.ensembl.org/Homo_sapiens/).
There are 22216 functional genes corresponding to 33860
transcripts in the categories of known and novel, and 1978
pseudogenes in this release. A Vega pseudogene set on chro-
mosomes 9 and 10, which was manually annotated and
curated by the international vertebrate genome annotation
(VEGA) project (28), was provided by the Vega project
leader Dr Ashurst through website http://vega.sanger.ac.uk/.
A total of 1031 pseudogenes were obtained from Vega.
Transcript-based sequence alignments
ESTmapper (29) was used to align EST, cDNA, Ensembl and
Vega transcripts onto human Build 35 genome. ESTmapper
uses a hash-index of 20mers in the genome to quickly locate
areas of the genome likely to contain the query, then invokes
the core of the sim4 algorithm (30) to produce a spliced align-
ment between the query and each genomic region selected.
Different cut-offs were applied to retain alignments from
mRNA and EST sequences due to their different qualities.
The retained alignments for all alignments must contain 50%
or more of the original sequence. For RefSeq and GenBank
mRNA sequences, alignments that have at least 70% of
sequence identity were retained; whereas, this sequence iden-
tity cut-off was raised to 95% for EST sequences. These less
stringent thresholds used for full-length cDNA sequences
allow additional alignments on locations other than its source
gene. The average number of alignment per sequence was
1.61, 19.87 and 1.38 for RefSeq, GenBank mRNA and EST,
respectively. The overall retention rate was 99.93, 95.03 and
84.55%, respectively.
ESTmapper was used to map Ensembl and Vega transcript
sequences onto human Build 35 genome because the exon
structure information was not provided in the original gene
FASTA ﬁles downloaded from the websites, but was needed
in this study to establish relationships between evidence and
genes. When there were multiple alignments for a single
gene, the alignment whose coordinates from ESTmapper
that overlap with the ones reported in the original ﬁles was
used. Because the genome used by Vega has incorporated
34 additional clones, the chromosomal locations of Vega
pseudogenes do not always correspond to the genome used
in this study (Dr Ashurst, personal communication). As a
result, only 667 out of 1031 Vega pseudogenes unambigu-
ously overlap their reported coordinates with ESTmapper
coordinates. For Ensembl genes, 22131 out of 22216 func-
tional genes and 1976 out of 1978 pseudogenes were mapped
onto the Build 35 genome with consistent locations.
Protein sequence alignments
Protein sequences from SWISS-PROT were mapped onto
human Build 35 genome using a combined method of
TBLASTN (31) and GeneWise (32). Sequences were initially
searched against the genome using TBLASTN with an
expectation score of <1 · 10
10. TBLASTN generated one
or more alignments for each protein-coding exon, which iden-
tiﬁed the approximate genomic locations of the putative
exons. The aligned genomic sequences were extracted with
additional 100 bp sequence on each side and joined together
in the order of the original protein sequence (see Figure 2). If
multiple sets of alignments were generated, as seen in gene
clusters, then each member of the set would have its own
extracted sequence deﬁned by the protein sequence. Then
GeneWise was run on this extracted sequence to produce
the ﬁnal protein alignments and report frameshifts and
in-frame stop codons when detected. This two-step process
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while not losing any structure information. The overall
mapping rate of the SWISS-PROT sequences was 95.03%
with an average of 5.73 alignments per sequence. The
mapping statistics are summarized in Table 1.
Expression evidence profiles
We constructed transcript (mRNA, EST) or protein expres-
sion proﬁles in three steps. Step one identiﬁes a best hit
for every sequence aligned on the genome. The minimum
requirement for a best hit is >98% identity with the genomic
sequence on >90% of the original sequence coverage.
By deﬁnition, a unique hit that passes the initial quality
thresholds is always a best hit. Additional rules were applied
to further narrow down the selection to one single alignment,
in the order of: identity percentage, splicing status (spliced
preferred over non-spliced) and coverage percentage. In rare
cases, there is more than one alignment showing the same
match statistics, then we would consider all of them as
best hits. In addition, there are 240 GenBank mRNAs and
6 RefSeq mRNAs already annotated and marked as pseudo-
genes. All the alignments from these known pseudogenes
are considered as non-best hits. For protein sequences, we
ﬁrst computed a frameshift rate for each GeneWise align-
ment. The frameshift rate is deﬁned as the sum of frameshifts
divided by the sum of the match length. The best hit was
picked with the lowest frameshift rate. If more than one
hit has the same lowest frameshift rate, then the same rules
used for transcripts are adapted here in order to determine a
single best hit. The percentage of unique best hits among
all the best hits was 98.79, 98.59 and 98.27 and 97.76 for
mapped RefSeqs, GenBank mRNAs, ESTs and SWISS-
PROT proteins, respectively.
Step two establishes association relationships between
evidence and genes through a collocation algorithm. This
algorithm matches the two alignments by their genomic
locations. If an evidence alignment overlaps with the exon
regions of a gene on the same strand, this evidence is con-
sidered to collocate with the gene. This association does
not require the two sequences to have sequence similarities
or share the same splice junction.
Step three collects supporting evidence to construct expres-
sion evidence proﬁles. For a transcript expression proﬁle,
all the collocated alignments from EST, GenBank mRNA
and RefSeq mRNA sequences are pooled together. Similarly,
a protein expression proﬁle is constructed for every gene
that has support from SWISS-PROT protein sequences. The
number of structure disruptions, i.e. frameshifts, presented
in the alignments of supporting evidence is calculated in
each proﬁle.
Pseudogene identification
Pseudogenes were identiﬁed through the following three pro-
cesses. First, genes with transcript proﬁles that do not contain
any best hits, regardless of protein proﬁle, are deﬁned as non-
transcribed pseudogenes. Second, genes with best hits from
their transcript proﬁles, but the corresponding protein proﬁles
lack best hit and contains frameshifts, are deﬁned as tran-
scribed pseudogenes. Third, genes without any transcript pro-
ﬁle, but with a protein proﬁle that lack best hit and contains
frameshifts, are also considered as non-transcribed pseudo-
genes since no detectable transcript evidence strongly sug-
gests that they have never been transcribed. Any remaining
genes are not considered as pseudogenes due to lack of
information.
Calibration of parameters
We applied the described process to identify pseudogenes
in Celera gene annotation from human and mouse. Celera
human annotation was based on human genome assembly
release R27 and mouse annotation was based on mouse
genome assembly release WGA3. Both gene sets were
manually annotated by expert annotators and pseudogenes
were carefully curated and ﬂagged. Using these gene sets
as reference, we varied and tested the criteria and thresholds
used in selecting best hits and identifying pseudogenes,
followed by thorough manual curation on the results. We
found that the thresholds used in this study were consistently
accurate for capturing annotated pseudogenes in both species
with minimum false negatives and false positives.
RESULTS
Completeness of evidence
An important consideration for our approach is the complete-
ness of transcript evidence to ensure coverage for the
functional genes. If the evidence is incomplete, then some
genes will not have primary cDNA coverage and could be
potentially misclassiﬁed as pseudogenes. We addressed this
problem by looking at successively increasing samples of
existing ESTs and their impact on our pseudogene analysis.
The full set of ESTs overlaps 20536 functional and
1159 pseudogenes from Ensembl. We randomly selected
ﬁve subsets of EST sequences with the number of sequences
being 1, 2, 3, 4 and 5 million per subset. The number of genes
supported by each subset increased from 18757 for 1 million
to 20524 for 5 million, while the number of pseudogenes
increased from 739 to 1158, respectively (see Table 2).
Using criteria of either no best hit in the supporting evidence,
or a complete lack of supporting ESTs, the number of
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Nucleic Acids Research, 2006, Vol. 34, No. 16 4479potential non-transcribed pseudogenes identiﬁed per subset
decreased from 3854 to 1531. Plotting the potential pseudo-
genes, in Figure 3, we showed that this number decreases
as the number of evidence increases, but it ﬂattens out
when the number of ESTs reaches 4 million. From the
whole genome EST mapping, we also observed a limited
number of genome regions covered by EST but not Ensembl.
This is consistent with a recent study (33) aimed at assessing
human protein-coding genes through longitudinal database
surveys, which suggests that the human gene count has
shown a static number at 28 000. The EST coverage for
human genes is approaching saturation and new sequence
submissions are predominantly extending known genes or
sampling new splice variants.
Validation of accuracy and sensitivity
To evaluate the performance of our process, we tested its dis-
criminative power on two sets of pre-deﬁned pseudogenes:
the manually annotated Vega pseudogenes from chromo-
somes 9 and 10 and the Ensembl pseudogene predictions.
Vega pseudogene validation
From the 667 Vega pseudogenes consistently located on the
NCBI Build 35 genome, transcript expression proﬁles were
constructable for 469 genes. In these 469 genes: 266 were
not supported by any best hits and, therefore, qualiﬁed as
non-transcribed pseudogenes; 150 were collocated with pro-
tein evidence from SWISS-PROT, but the protein proﬁles
suggested 92 of them are not translated by our deﬁnition.
In the remaining 198 genes without transcript evidence, we
were able to construct protein proﬁles for 120, of which
93 met the criteria for pseudogenes. In total, 451 (266 +
92 + 93) out of the 536 genes that were supported by any
expression evidence are conﬁrmed as pseudogenes. The over-
all validation rate for mapped Vega pseudogene is 76.57%.
These numbers are summarized in Table 3. We excluded
from our analysis the 78 genes for which we could not
construct either expression proﬁles. After manual review,
we established that these pseudogenes were annotated based
on protein evidence not included in our snapshot of the
SWISS-PROT database.
The Vega gene set contains both processed and non-
processed pseudogenes. For the purpose of verifying the sen-
sitivity of our method towards the detection of non-processed
pseudogenes, we classiﬁed genes that lack introns as pro-
cessed pseudogenes, while the rest as the non-processed,
although some of the multiple-exon forms may actually
represent partially processed pseudogenes (1). Of the 667
pseudogenes from the original dataset, 153 contain intronic
sequences representing 23% non-processed pseudogenes.
Of the 451 genes conﬁrmed as pseudogenes by our method,
85 are non-processed, which represents 19% of the validated
Table 1. Summary of gene and evidence mapping
Gene and evidence Total sequences Criteria Mapped sequences Percentage Alignments per sequence
Ensembl functional genes 22216 Location verification 22131 99.62% NA
Ensembl pseudogenes 1978 Location verification 1976 99.90% NA
Vega chromosome 9 and 10 pseudogenes 1031 Location verification 667 64.69% NA
Refseq 22887 70% identity, 50% length 22871 99.93% 1.61
GenBank mRNA 195073 70% identity, 50% length 185385 95.03% 19.87
EST 6020341 95% identity, 50% length 5089981 84.55% 1.38
Swiss-Prot 11777 TBLASTN <1 · 10
10 11192 95.03% 5.73
Table 2. Summary of EST profiling of Ensembl genes and pseudogenes
# of EST
mapped
Overlapping
Ensembl genes
Overlapping Ensembl
pseudogenes
Non-transcribed
Ensembl genes
Non-transcribed Ensembl
pseudogenes
Total non-transcribed
pseudogenes
1 million 18757 739 2942 912 3854
2 million 19780 911 1874 802 2676
3 million 20161 1007 1388 725 2113
4 million 20387 1090 1104 662 1766
5 million 20524 1158 918 613 1531
Total 20536 1159
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Figure 3. Potential pseudogenes as a function of EST evidence used. Total
potential pseudogenes without best hits or lack of any EST hits plotted against
the amount of EST evidence used.
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tion of non-processed pseudogenes (23%) in the original
dataset. This indicates that our approach can detect both
processed and non-processed pseudogenes without bias.
Ensembl pseudogene validation
We applied the same validation procedure to the processed
pseudogenes from Ensembl prediction. The results are shown
in Table 3. We obtained consistent mapping of 1974 out of
1978 Ensembl pseudogenes. The transcript (EST and mRNA)
expression proﬁles for 1611 pseudogenes were constructed.
Of these, 977 genes were considered as non-transcribed pseu-
dogenes due to lack of best hits. For the remaining 634 genes
potentially active at transcription, we could only construct
protein expression proﬁles for 380 genes based on SWISS-
PROT sequences. Of these, 311 were identiﬁed as transcribed
pseudogenes. There are an additional 234 genes supported
only by protein evidence. Of these, 212 genes passed the
pseudogene thresholds. In total 1500 (977 + 311 + 212) are
non-evidential at either the transcription or translation level.
The overall validation rate is 81.30% (1500/1845).
Validation statistics
We achieved a validation rate of 76.57 and 81.30% on Vega
and Ensembl pseudogenes, respectively. However, this rate
was calculated without considering the fact that the protein
sequences used for proﬁling in this study were just a subset
of the dataset used by Vega and Ensembl annotation process.
As a result, some of the genes do not show any protein
evidence in our analysis. If our protein data were expanded
to include sequences in TrEMBL or NCBI NRAA, the valida-
tion rate would be higher since more genes could be sub-
jected to evaluation. However, these protein datasets would
also generate more false positives due to the inclusion
of computational predicted translations. There were 53 and
262 genes in Vega and Ensembl, respectively, which were
supported by best hits of transcript evidence, but not covered
by any protein from SWISS-PROT. If these gene counts
were factored out, the validation rate would be increased to
84 and 94% for Vega and Ensembl, respectively. Such
sensitivity provides conﬁdence in our method to identify
true pseudogenes.
Our analysis depends on an accurate alignment of evidence
sequences, which determines the assignment of best hits.
There is a potential for error in a small number of ESTmapper
and GeneWise alignments, typically less than 1 out of 10
5
bases mapped due to algorithmic biases (Peter Li, unpubli-
shed data). In addition, true variations between mRNA
sequences and the ﬁnished human genome such as polymor-
phisms can lead to frame shifts (34) and incorrect assignment
of best hits. These allele-speciﬁc pseudogenes should still be
considered as pseudogenes (35,36) and do not invalidate the
premise behind our approach.
We estimate 10–20% of the genes are potentially false
negatives (pseudogenes wrongly inferred as genes) by our
method, because we cannot exclude the possibility that the
original protein evidence might be partial or might represent
defective proteins. Although they qualify as best hits, they do
not represent real expression products. Such low quality
sequences directly affect the outcomes of gene annotation.
Extra effort should be paid to identify and exclude them
before being used as evidence. On the other hand, the fact
that these genes (potentially false negatives by our method)
present transcriptional activities, and possibly translational
activities or intact structure without disruptions may cast a
doubt on their pseudogene status previously assigned by
their respective sources. To estimate the rate of false positives
(genes wrongly inferred as pseudogenes), we examined the
asymptotic limit of ESTs to identify pseudogenes. Under
the assumption that as we enlarge the mapped EST set,
more candidate pseudogenes will overlap a best hit EST
and thus convert to a transcribed gene. From Figure 3, the
decrease of pseudogenes asymptotically approaches to
1310 using an exponential probability model of ‘pseudogene
failures’, this gives us an upper bound of false positive
rate at 15%. An independent estimate of 10% came from
manual curation of the pseudogenes identiﬁed by this pipe-
line on the Celera human gene set. In the opinion of the
Table 3. Summary statistics for the validation of Vega and Ensembl pseudogenes
Categories Vega Ensembl
# % of respective
category
%o f
total
# % of respective
category
%o f
total
Original 1031 1978
Aligned with consistent locations 667 1974
cDNA support 469 1611
No cDNA best hits (non-transcribed pseudogene) 266 100.00 45.16 977 100.00 52.95
With cDNA best hits 203 642
Swiss-Prot protein support 150 380
No best hits & presence of
frameshifts (transcribed pseudogene)
92 61.33 15.62 311 81.84 16.86
No cDNA support 198 634
Swiss-Prot protein support 120 234
No best hits and presence of
frameshifts (non-transcribed pseudogene)
93 77.50 15.79 212 90.60 11.49
No support from cDNA & Swiss-Prot 78 129
Non-transcribed pseudogenes 78 NA NA 129 NA NA
Total genes supported by evidence 589 1845
Total pseudogenes validated 451 NA 76.57 1500 NA 81.30
Nucleic Acids Research, 2006, Vol. 34, No. 16 4481expert annotators, the major sources of false positives were:
(i) error in the assignment of best hits mostly due to the
discrepancies between the evidence sequence and the geno-
me sequence and (ii) evidence that is not included in
the pipeline, e.g. sequences from NRAA or TrEMBL. The
feedback from manual curation had been incorporated into
the algorithm to calibrate the parameters to minimize false
positives.
Identification of pseudogenes from ensembl genes
Ensembl human annotation release 27.35a.1 contains 22216
genes in the categories of known and novel as functional
genes. We retained 22131 genes after mapping to B35 and
verifying location consistency with their original coordinates.
Transcript expression proﬁles can be constructed for 21655
genes. Of these, 1018 were considered as non-transcribed
pseudogenes due to lack of best hits in their proﬁles. An addi-
tional 412 genes only have protein evidence. After checking
properties of: (i) lack of best hits and (ii) presence of frame-
shifts, 182 genes were identiﬁed as non-transcribed pseudo-
genes. We then examined the group of genes with best hits
from mRNA or EST evidence. There are 20637 genes in this
category. Of these, 13803 genes had protein proﬁles estab-
lished. From these, 811 genes were not supported by any
best hit from protein and contained frameshifts. We consider
these 811 genes as transcribed pseudogenes since we have
expression evidence at transcription, but no evidence of intact
translation. However, a genome assembly without sequence
or assembly errors may be required before this interpretation
can be made with more certainty. This group of pseudogenes
are currently considered as non-functional at translation, but
with recognition that they are potentially functional and may
have to be re-evaluated in the future.
We concluded that 2011 (1018 + 182 + 811) Ensembl
predicted genes have been identiﬁed as pseudogenes based
on expression evidence proﬁling (The gene list is available
in the Supplementary Data). Of these, 1200 genes are non-
transcriptional and 811 genes are non-translational. This
number represents 9.1% (2011/22 067) of the total Ensembl
genes. Checking the exon structure, the number of pseudo-
genes with more than one and two exons is 1341 (66.68%)
and 815 (40.53%), respectively, suggesting at least 40% of
them are non- or partially processed pseudogenes.
Evaluation of pseudogenes identified from
ensembl genes
To evaluate the accuracy of our methods, we conducted
in-depth analysis of the pseudogenes identiﬁed above to
evaluate whether their functional parental genes exist and
to understand the underlying mechanisms for pseudogene
origination by comparing exon structures between each
pair of pseudogene and their respective parent. A subset of
526 genes from this group was selected because they are
supported by evidence from RefSeq mRNA sequences. The
genomic alignments of these RefSeq sequences were used
to track and identify parental genes. To qualify for a parental
gene, we require that the transcript of this gene must be
supported by the best hits of the RefSeq sequences and
covers at least 50% of the transcript length of the respective
pseudogene. Based on the above criteria, 288 genes had
putative parental genes identiﬁed. These parental genes were
Ensembl genes in the categories of known or novel and
located somewhere else in the genome. Of the 288 pseudo-
genes, 239 were assigned to a unique parental gene while
49 were associated to more than one paralogous parent. Due
to a very high degree of sequence identity among those
paralogs, it is impossible to distinguish which one is the
real parent of the respective pseudogene.
We then compared the exon structure between each pair of
genes, and divided the gene pairs into four different groups.
Group A contains the gene pairs in which the pseudogene
is single-exon and the parental gene is multi-exon, represen-
tative of the ‘processed pseudogenes from retrotransposition’
model. Group B contains the gene pairs that both genes lack
intronic sequences. It is difﬁcult to determine which mecha-
nism was responsible for the formation of these pseudogenes
if simply judged by the exon structure. Group C contains the
gene pairs in which both genes are spliced and the parental
gene has an equal or a greater number of exons than the
pseudogene. In Group D, the pseudogenes contain a single
putative intron that does not exist in the respective parental
genes. Table 4 summarized the detailed statistics for the
four groups described above. Based on the exon structure
and the result of comparison between pseudogenes and
parental genes, it is most likely that the 112 genes in the
group C are non-processed pseudogenes. This number repre-
sents 38.89% of the 288 pseudogenes with putative parental
genes identiﬁed. The percentage is consistent with the calcu-
lation from the previous section based on the total identiﬁed
pseudogenes in which the fraction of non-processed pseudo-
genes is 40.53% when considering genes with more than two
exons as the non-processed.
Group D represents some interesting gene pairs that were
investigated further. We found that, in most of the cases,
the putative intron present in the pseudogene appears to
be the result of the insertion of transposons or other DNA
sequence after retrotransposition. However, we also discov-
ered cases where the intron was artiﬁcially created by the pre-
diction algorithm. For instance, gene ENSG00000188712
was collocated with RefSeq NM_001004484 and several
other protein sequences from SWISS-PROT. All of the pro-
tein sequences contain a frameshift that resides within the
region where the intron locates. This artiﬁcial intron bypasses
the defect so that the gene does not appear to be disrupted
Table 4. Comparison of exon structures between Ensembl pseudogenes and
their parental genes from the 288 identified pairs
Categories Pairs of genes
Total Relationship of pseudo to
parent
One-to-one One-to-many
Group A: pseudogene
single-exon,
parent multi-exon
109 (37.85%) 102 7
Group B: both single-exon 42 (14.58%) 27 15
Group C: both multi-exon 112 (38.89%) 96 16
Group D: pseudogene 2-exon,
parent single-exon
25 (8.68%) 14 11
Total 288 239 49
4482 Nucleic Acids Research, 2006, Vol. 34, No. 16in structure. This result demonstrates that our approach is
able to capture this type of ‘disrupted’ processed pseudogenes
(by natural or artiﬁcial means) that are otherwise missed by
methods that rely on the absence of introns.
Functional classification of pseudogenes
We grouped the 2011 pseudogenes using Ensembl protein
family classiﬁcation (http://www.ensembl.org/). Table 5
summarizes the top 10 functional classes. These 10 classes
represent multigene families and many of them are highly
expressed. All of them have been previously identiﬁed as
having a large number of pseudogenes in human (11,12).
Other than 308 (15.3%) unclassiﬁed pseudogenes, the most
frequent pseudogenes come from ribosomal protein genes,
for which we found 137 (6.8%) copies of the combined
set of all types of ribosomal proteins. A key glycolytic
enzyme involved in energy production, Glyceraldehyde
3-phosphate dehydrogenase (GAPDH), has been reported
to have more than 400 processed GAPDH pseudogenes
in mouse (20). In human, however, results from previous
studies were not consistent. One study (12) identiﬁed 78
processed pseudogenes while the other (11) did not ﬁnd
any. Through our method, we identiﬁed four GAPDH
pseudogenes (ENSG00000163410, ENSG00000188796,
ENSG00000188885 and ENSG00000183299). All of these
four genes are partial compared with the functional counter-
part. They are in the category of novel and have no orthologs
from mouse or rat according to Ensembl. The ﬁrst two genes
have a single-exon and the latter two have four exons each,
but with suspiciously small intron sizes (2–5 bp) for the
majority of the introns. Another gene family, Cytochrome
P450 (CYP), is relatively pseudogene-rich with 58 known
pseudogenes in human, but these pseudogenes are sometimes
hard to identify due to their almost intact structures (37). In
fact, only one CYP pseudogene was identiﬁed among
12 000 annotated pseudogenes (http://bioinfo.mbb.yale.
edu/genome/pseudogene/human-all/index.html). We identi-
ﬁed eight copies, and six of them are full-length or nearly
full-length pseudogenes with multi-exon (exon number
ranges from 5 to 12) structures. The remaining two genes,
ENSG00000198461 and ENSG00000130612, have only 1
and 2 exons with a length of 132 and 309 bp, respectively,
representing the detritus exons type of pseudogenes (37). In
addition, we identiﬁed ENSG00000184235 as a transcribed
protein tyrosine phosphatase (PTP) pseudogene in agreement
with a recent study on PTPs (18).
DISCUSSION
We presented a novel method for the systematic identiﬁcation
and validation of pseudogenes from a given set of annotation.
Because the annotated gene sets are derived from evidence,
our process reevaluates the relationship of the genes and
their expression evidence, such as ESTs, mRNAs and
proteins, and assesses their functionality through a detailed
proﬁling of supporting evidence in a whole genome-scale.
This global view of properly assigning evidence to the gene
overcomes the typical shortcomings of gene annotation from
the local pattern of supporting transcription and translation
evidence. Consequently, we can infer whether a gene is func-
tional or disabled, and at which level during the process of
gene expression with a mechanism that is universally applica-
ble to all types of pseudogenes regardless of their individual
structure and sequence features, and the synonymous and
non-synonymous nucleotide substitution rates. To our know-
ledge, this is the ﬁrst report that uses whole genome expres-
sion evidence to systematically identify pseudogenes through
a computational approach. This method was designed as a
post-processing step following computational gene annota-
tion to identify potential incorrect annotations and facilitate
the subsequent efforts with manual curation. Because the
annotated genes form the foundation for the subsequent
experimental design and computational work on a genome,
it is critical that high quality annotation was established
from the outset.
The strength of our method depends on the relative
completeness of transcriptional and translational evidence.
For species with deep cDNA and protein coverage, such as
human and mouse, this method would be appropriate to
validate gene annotations. However, for species with limited
evidence, it may not be appropriate. In addition, the inherent
error rate of transcriptome sequencing is an important factor
in the interpretation of transcript alignments on the genome:
the best alignment of a given transcript may not be identi-
ﬁable if there are too many errors. This will become more
critical in the future when researchers apply the next genera-
tion of sequencing technology to the transcriptome (38)
whose the initial error rate might be higher than the intrinsic
polymorphism or mutation rate. While this is resolvable by
constructing consensus genome sequence from multiple
copies, it raises the risk of collapsing transcripts from
different paralogous genes in transcriptome sequencing.
The method of whole genome expression sequence proﬁl-
ing contains two important features. First, it is equally pow-
erful for the identiﬁcation of processed and non-processed
pseudogenes as demonstrated by validating manually curated
Vega pseudogenes. The latter type of pseudogenes has been
thought to be a major source of annotation errors (16,33).
This is proved to be true from our results since 40% of the
2011 pseudogenes identiﬁed from Ensembl genes are non-
processed pseudogenes with multi-exon gene structures.
Second, our method is able to identify at which level the
loss of gene expression most likely occurs. This ability allows
the detection of transcriptionally active pseudogenes, which
represent a challenge to the annotation process because of
the existence of both homology and expression evidence.
Additionally, undetected transcribed pseudogenes may lead
to misinterpretation of experimental results from both gene
Table 5. Functional classification of pseudogenes
Name Number
Olfactory receptor 53
Keratin type I/II 24
Immunoglobulin 21
Peptidyl-prolyl cis-trans isomerase 17
Heterogeneous nuclear ribonucleoprotein 16
HMGI/II (high mobility group) 14
Dynein heavy chain 12
Nucleophosmin 12
40S ribosomal S2 11
Elongation factor 1 alpha 10
Nucleic Acids Research, 2006, Vol. 34, No. 16 4483expression and genotyping assays and from microarrays
intended for functional genes. We discovered through the
whole genome expression proﬁling that 14% (92/667) and
16% (311/1974) of the pseudogenes from Vega and Ensembl,
respectively, have supporting expression evidence from
cDNA and EST sequences. These numbers are well in line
with data previously reported. This signiﬁcant percentage of
transcribed pseudogenes deserves more attention from assay
and array developers because it makes the primer and probe
selection more difﬁcult in order to ensure that they precisely
amplify the expected gene product. Correctly characterizing
all the pseudogenes allows accurate design of locus-speciﬁc
assays and microarrays for functional genes, many of which
are clinically important (39,40). Further studies on trans-
cribed pseudogenes will add to our understanding of their
potential roles as non-coding RNA genes or other new
types of functional elements.
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